Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry

Autor: Ofer Kobo, Majdi Saada, Clemens von Birgelen, Pim A L Tonino, Andres Íñiguez-Romo, Ole Fröbert, Majdi Halabi, Rohit M Oemrawsingh, Jawed Polad, Alexander J J IJsselmuiden, Marco Roffi, Adel Aminian, Mamas A Mamas, Ariel Roguin
Rok vydání: 2022
Předmět:
Zdroj: European Heart Journal - Quality of Care and Clinical Outcomes.
ISSN: 2058-1742
2058-5225
Popis: Background Multisite artery disease is considered a ‘malignant’ type of atherosclerotic disease associated with an increased cardiovascular risk, but the impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention (PCI) is unknown. Methods Patients enrolled in the large, prospective e-Ultimaster study were grouped into (1) those without known prior vascular disease, (2) those with known single-territory vascular disease, and (3) those with known two to three territories (i.e coronary, cerebrovascular, or peripheral) vascular disease (multisite artery disease). The primary outcome was coronary target lesion failure (TLF), defined as the composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization at 1-year. Inverse propensity score weighted (IPSW) analysis was performed to address differences in baseline patient and lesion characteristics. Results Of the 37 198 patients included in the study, 62.3% had no prior known vascular disease, 32.6% had single-territory vascular disease, and 5.1% had multisite artery disease. Patients with known vascular disease were older and were more likely to be men and to have more co-morbidities. After IPSW, the TLF rate incrementally increased with the number of diseased vascular beds (3.16%, 4.44%, and 6.42% for no, single, and multisite artery disease, respectively, P Conclusions Patients with previously known vascular disease experienced an increased risk of adverse cardiovascular events and mortality post-PCI. This risk is highest among patients with multisite artery disease. Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02188355.
Databáze: OpenAIRE
Externí odkaz: